{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:32:37Z","timestamp":1764333157881,"version":"3.46.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04096-3","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:22:44Z","timestamp":1764332564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological complete response to pembrolizumab in recurrent retroperitoneal dedifferentiated liposarcoma with high tumor mutational burden: a case report"],"prefix":"10.1186","volume":"23","author":[{"given":"Shun","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiliang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ariizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirosuke","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyasu","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"13","key":"4096_CR1","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1200\/JCO.2012.44.3747","volume":"31","author":"A Gronchi","year":"2013","unstructured":"Gronchi A, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31(13):1649\u201355.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4096_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1097\/SLA.0000000000001447","volume":"263","author":"A Gronchi","year":"2016","unstructured":"Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): A report on 1007 patients from the Multi-institutional collaborative RPS working group. Ann Surg. 2016;263(5):1002\u20139.","journal-title":"Ann Surg"},{"issue":"2","key":"4096_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jamcollsurg.2013.10.009","volume":"218","author":"EZ Keung","year":"2014","unstructured":"Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. J Am Coll Surg. 2014;218(2):206\u201317.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"4096_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, Hartmann JT, Sch\u00f6ffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus Ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415\u201323.","journal-title":"Lancet Oncol"},{"issue":"9829","key":"4096_CR5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386.","journal-title":"Lancet"},{"issue":"10","key":"4096_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4096_CR7","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1038\/s41467-022-30496-0","volume":"13","author":"MM Gounder","year":"2022","unstructured":"Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, et al. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022;13(1):3406.","journal-title":"Nat Commun"},{"issue":"11","key":"4096_CR8","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501.","journal-title":"Lancet Oncol"},{"key":"4096_CR9","doi-asserted-by":"crossref","unstructured":"Seligson ND, Chen JL, Goodrich AC, Van Tine BA, Campbell JD, Richards AL et al. A multicenter, randomized, non-comparative, phase II study of nivolumab\u2009\u00b1\u2009ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. J Immunother Cancer. 2024;12(9):e009472.","DOI":"10.1136\/jitc-2024-009472"},{"key":"4096_CR10","doi-asserted-by":"publisher","first-page":"102115","DOI":"10.1016\/j.ctrv.2020.102115","volume":"91","author":"MMT Zhu","year":"2020","unstructured":"Zhu MMT, Shenasa E, Nielsen TO. Sarcomas: immune biomarker expression and checkpoint inhibitor trials. Cancer Treat Rev. 2020;91:102115.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"4096_CR11","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1097\/01.pas.0000170343.09562.39","volume":"29","author":"MB Binh","year":"2005","unstructured":"Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagace R, et al. MDM2 and CDK4 immunostainings are useful in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29(10):1340\u20137.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"4096_CR12","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/s41379-019-0312-y","volume":"32","author":"AR Dancsok","year":"2019","unstructured":"Dancsok AR, Setsu N, Gao D, Blay JY, Thomas D, Maki RG, et al. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Mod Pathol. 2019;32(12):1772\u201385.","journal-title":"Mod Pathol"},{"issue":"1","key":"4096_CR13","doi-asserted-by":"publisher","first-page":"1747340","DOI":"10.1080\/2162402X.2020.1747340","volume":"9","author":"AR Dancsok","year":"2020","unstructured":"Dancsok AR, Gao D, Lee AF, Steigen SE, Blay JY, Thomas DM, et al. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020;9(1):1747340.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4096_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.","journal-title":"Genome Med"},{"issue":"5","key":"4096_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3892\/ol.2021.12614","volume":"21","author":"L Xu","year":"2021","unstructured":"Xu L, Xie X, Shi X, Zhang P, Liu A, Wang J, et al. Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma. Oncol Lett. 2021;21(5):353.","journal-title":"Oncol Lett"},{"issue":"21","key":"4096_CR16","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1002\/cam4.4725","volume":"11","author":"M Gan","year":"2022","unstructured":"Gan M, Zhang C, Qiu L, Wang Y, Bao H, Yu R, et al. Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients. Cancer Med. 2022;11(21):4070\u20138.","journal-title":"Cancer Med"},{"issue":"1","key":"4096_CR17","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1038\/s41467-025-58678-6","volume":"16","author":"A Soupir","year":"2025","unstructured":"Soupir A, Ospina OE, Hampton O, Churchman M, Radmacher M, Hedges D, et al. Genomic, transcriptomic, and Immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes. Nat Commun. 2025;16(1):4206.","journal-title":"Nat Commun"},{"issue":"1","key":"4096_CR18","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1186\/s12885-020-07456-2","volume":"20","author":"W Liu","year":"2020","unstructured":"Liu W, Tong H, Zhang C, Zhuang R, Guo H, Lv C, et al. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma. BMC Cancer. 2020;20(1):1035.","journal-title":"BMC Cancer"},{"issue":"2","key":"4096_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"6","key":"4096_CR20","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-19-1824","volume":"26","author":"EZ Keung","year":"2020","unstructured":"Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, et al. Correlative analyses of the SARC028 trial reveal an association between Sarcoma-Associated immune infiltrate and response to pembrolizumab. Clin Cancer Res. 2020;26(6):1258\u201366.","journal-title":"Clin Cancer Res"},{"key":"4096_CR21","doi-asserted-by":"publisher","first-page":"e2200068","DOI":"10.1200\/PO.22.00068","volume":"6","author":"TKY Tay","year":"2022","unstructured":"Tay TKY, Yeong JPS, Chen EX, Sam XX, Lim JX, Chan JY. Soft tissue leiomyosarcoma with microsatellite Instability, high tumor mutational Burden, and programmed death Ligand-1 expression showing pathologic complete response to pembrolizumab: A case report. JCO Precis Oncol. 2022;6:e2200068.","journal-title":"JCO Precis Oncol"},{"key":"4096_CR22","doi-asserted-by":"publisher","first-page":"103773","DOI":"10.1016\/j.critrevonc.2022.103773","volume":"177","author":"D Presti","year":"2022","unstructured":"Presti D, Dall\u2019Olio FG, Besse B, Ribeiro JM, Di Meglio A, Soldato D. Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review. Crit Rev Oncol Hematol. 2022;177:103773.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"16","key":"4096_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21037\/atm.2019.07.43","volume":"7","author":"B Zheng","year":"2019","unstructured":"Zheng B, Wang J, Cai W, Lao I, Shi Y, Luo X, et al. Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas. Ann Transl Med. 2019;7(16):387.","journal-title":"Ann Transl Med"},{"issue":"5","key":"4096_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436\u201343.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"4096_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920\u20138.","journal-title":"Nat Med"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04096-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04096-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04096-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:22:45Z","timestamp":1764332565000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04096-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4096"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04096-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for ethics approval for this case report was waived by the ethics committee of the Niigata University School of Medicine. Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of the manuscript and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"449"}}